BioSpace News Archive

Lexicon Pharmaceuticals, Inc. will host its 2020 annual meeting of stockholders in a virtual format only due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants..

G1 Therapeutics, Inc. announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company update at the 19th Annual Needham Virtual Healthcare Conference on April 14, 2020 at 2:10 p.m. ET.

IRADIMED CORPORATION announced that it expects to report first quarter 2020 revenue of $8.6 million to $8.7 million and is withdrawing its first quarter and full year 2020 financial guidance due to the uncertainty created by COVID-19.

The only FDA authorized palm-sized system for COVID-19 testing enables broader use across healthcare facilities and closer to the patients with rapid results

CROMSOURCE, an international contract research organization with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company.

ReNeuron Group plc announced that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company’s proprietary exosomes to deliver novel therapeutics.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He , Chairman & CEO will present an overview of the company and provide a business update at the Solebury Trout V

KalVista Pharmaceuticals, Inc. today announced potential impact of coronavirus disease 2019 (COVID-19) on its ongoing operations

Exicure, Inc. reported Timothy P. Walbert, Chairman, President and CEO of Horizon Therapeutics plc, will succeed Chad Mirkin, Ph.D. as Chairman of Exicure’s Board of Directors.

Lumasiran is the First Potential Therapeutic to Demonstrate Substantial Reduction in Urinary Oxalate Excretion